دسترسی یکساله به بیش از ۵۰۰ ژورنال روز جهان موجود در سامانه
-
http://medilib.ir
- ﻣﺪﺕ ﺯﻣﺎﻥ : 365 ﺭﻭﺯ
قیمت : 3,800,000 تومان- قیمت ویژه : 1,900,000تومان
Maternal smoking and multiple sclerosis risk in offspring: A further clue of prenatal environmental triggers
Emilio Portaccio and Pietro Iaffaldano
doi : 10.1177/13524585231224667
Volume 30 Issue 2, February 2024
Optic nerve topography in multiple sclerosis diagnostic criteria: Existing knowledge and future directions
Angela Vidal-Jordana , Jaume Sastre-Garriga , Mar Tintoré , Alex Rovira and Xavier Montalban
Neuropsychological assessment in MS is outdated and is in need for innovation: Yes
Pauline T Waskowiak, Marit FL Ruitenberg and Hanneke E Hulst
Neuropsychological assessment in MS is outdated and in need for innovation: NO
Dawn Langdon
Neuropsychological assessment in MS is outdated and in need for innovation: Commentary
Ralph H B Benedict
Plasma glial fibrillary acidic protein levels correlate with paramagnetic rim lesions in people with radiologically isolated syndrome
Raphael Schneider , Koroboshka Brand-Arzamendi, Timothy Reynold Lim, Lisa Eunyoung Lee , Melanie Guenette, Suradech Suthiphosuwan, Aditya Bharatha and Jiwon Oh
White matter paramagnetic rim and non-rim lesions share a periventricular gradient in multiple sclerosis: A 7-T imaging study
Alessandro Miscioscia , Constantina A Treaba , Valeria T Barletta , Elena Herranz, Jacob A Sloane , Elena Barbuti and Caterina Mainero
Concurrent administration of serotonergic antidepressants and ozanimod in participants with relapsing multiple sclerosis from the open-label extension DAYBREAK trial
Robert T Naismith , Jeffrey A Cohen , Amit Bar-Or, Giancarlo Comi , Krzysztof W Selmaj, Hans-Peter Hartung, James K Sheffield, Anthony Krakovich, Daniel Tatosian, Chun-Yen Cheng, Jennifer Reardon, Vadim Khaychuk, Jon V Riolo, Diego Silva and Bruce AC Cree
Risk of cardiovascular disease in patients with multiple sclerosis treated with fingolimod compared to natalizumab: A nationwide cohort study of 2095 patients in Denmark
Elisabeth Framke , Lau Caspar Thygesen, Morten Malmborg, Morten Schou, Finn Sellebjerg and Melinda Magyari
University education facilitates uptake of disease-modifying therapies for multiple sclerosis: A community-based study using the UK MS Register
Joyutpal Das , David J Rog, Rod Middleton , Jeff W Rodgers and Richard Nicholas
Smoking during pregnancy and risk of multiple sclerosis in offspring and mother: A Danish nationwide register-based cohort study
Nete Munk Nielsen, Morten Frisch , Sanne G?rtz, Egon Stenager, Kristin Skogstrand , David M Hougaard, Alberto Ascherio, Klaus Rostgaard and Henrik Hjalgrim
Final analysis of 379 pregnancy outcomes after exposure to dimethyl fumarate in a prospective international registry
Kerstin Hellwig, David Rog, Christopher McGuigan, Maria K Houtchens , Denise R Bruen, Oksana Mokliatchouk, Filipe Branco *, Seth Levin, Nicholas Everage and Xiaochen Lin
The Response Study: A French registry on pregnancy in women with MS and related disorders and their children up to 6 years—Protocol, recruitment status, and baseline characteristics
Sandra Vukusic , Bertrand Bourre, Romain Casey , Kumaran Deiva, Anne-Marie Guennoc, Christine Lebrun-Frenay , Emmanuelle Leray, Fabien Rollot, Lakhdar Benyahya, Catherine Girod, Romain Marignier and Elisabeth Maillart On Behalf of RESPONSE, OFSEP, and SFSEP Investigators
Use of multiple sclerosis disease-modifying therapies during pregnancy in France: Nationwide study between 2010 and 2021
Morgane Swital , Jérôme Drouin, Sara Miranda, Serge Bakchine, Jérémie Botton and Rosemary Dray-Spira
Association between demographics, socioeconomics, and disease-related factors and the perception of stigma in people with MS
Mahsa Ghajarzadeh , Kathryn C Fitzgerald , Ellen M Mowry and Bardia Nourbakhsh
Clinical and radiological correlates of apathy in multiple sclerosis
Francesco Tazza , Simona Schiavi, Elisa Leveraro, Maria Cellerino, Giacomo Boffa, Stefania Ballerini, Mara Dighero, Antonio Uccelli , Elvira Sbragia , Kenda Aluan , Matilde Inglese and Caterina Lapucci
Extended interval dosing of ocrelizumab in patients with multiple sclerosis is not associated with meaningful differences in disease activity
Nicole Bou Rjeily , Kathryn C Fitzgerald and Ellen M Mowry
Control of disease activity with large extended-interval dosing of rituximab/ocrelizumab in highly active pediatric multiple sclerosis
Melany Venet, Anne Lepine, Adil Maarouf , Damien Biotti , Clémence Boutiere, Olivier Casez, Mikael Cohen , Pierre Durozard, Sarah Demortière, Laetitia Giorgi, Elisabeth Maillart , Guillaume Mathey, Laure Mazzola, Audrey Rico, Jean-Philippe Camdessanche, Kumaran Deiva, Jean Pelletier and Bertrand Audoin ; under the aegis of the French Multiple Sclerosis Society
Exploring the effects of extended interval dosing of natalizumab and drug concentrations on brain atrophy in multiple sclerosis
Alyssa A Toorop , Samantha Noteboom , Martijn D Steenwijk, Job W Gravendeel, Bas Jasperse, Frederik Barkhof , Eva MM Strijbis , Theo Rispens , Menno M Schoonheim , Zoé LE van Kempen and Joep Killestein
Rituximab and pregnancy: Late-onset neutropenia in a 2-month infant whose mother received rituximab 2 weeks prior to childbirth
Natalia Gonzalez Caldito , Edith L Graham and Elena Grebenciucova
Anti-CD20 therapy in pregnancy: Balancing risks and benefits
Sandra Thiel and Kerstin Hellwig
Advancing assessment of cognitive change in multiple sclerosis: Seeking valid and sensitive approaches beyond simple cut-offs
Response to letter to the editor “Advancing assessment of cognitive change in multiple sclerosis: Seeking valid and sensitive approaches beyond simple cut-offs�
